---
title: "CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline advances driving raised guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295811349.md"
description: "Q2 2026 saw revenue surge to $101.9M and adjusted EBITDA to $58.7M, driven by DefenCath and Melinta. A new multi-year supply deal covers all top U.S. dialysis providers, and pipeline progress includes positive phase III data for REZZAYO. FY 2026 guidance was reaffirmed and raised.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T13:55:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295811349.md)
  - [en](https://longbridge.com/en/news/295811349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295811349.md)
generator: "portal-rs"
---

# CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline advances driving raised guidance

Q2 2026 saw revenue surge to $101.9M and adjusted EBITDA to $58.7M, driven by DefenCath and Melinta. A new multi-year supply deal covers all top U.S. dialysis providers, and pipeline progress includes positive phase III data for REZZAYO. FY 2026 guidance was reaffirmed and raised.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRMD.US](https://longbridge.com/en/quote/CRMD.US.md)

## Related News & Research

- [CRMD: Strong revenue growth, pipeline expansion, and financial flexibility drive continued value creation](https://longbridge.com/en/news/298461323.md)
- [CRMD: Diversified portfolio, strong cash flow, and new market opportunities drive growth and expansion](https://longbridge.com/en/news/298491477.md)
- [Unicycive Therapeutics outlines oxylanthanum carbonate program for hyperphosphatemia in dialysis patients](https://longbridge.com/en/news/298495072.md)
- [FREEM: Expansion into manufacturing services targets a 20x larger market and EBITDA positivity by 2028](https://longbridge.com/en/news/298413697.md)
- [TIG: Returned to operating profit with strong EBITDA growth and strategic review nearing completion](https://longbridge.com/en/news/298178752.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**